ANI Pharma rises as rare-disease drugs drive quarterly results beat
** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 11.8% to $61 premarket ** Co reports Q4 revenue of $190.6 mln, beating analysts' average estimate of $175.4 mln, on strong demand for rare-disease drugs Iluvien and Yutiq - data compiled by LSEG ** Posts adj. Q4 profit of $1.63 per share vs estimates of $1.44 ** Stock has fallen 8.9% in past 12 months (Reporting by Padmanabhan Ananthan) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on ANI Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates
Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 2.05 Vs. IBES Estimate USD 1.3
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma